Dennis Bittner, PhD

Results from the largest population-based, case-control study on the link between incretin therapy and pancreatitis conducted to date indicate that treatment with this class of medications does not confer increased risk of developing pancreatitis.

Combination treatment with insulin degludec and liraglutide was associated with long-term reductions in HbA1c, reduced hypoglycemia risk, and fewer gastrointestinal side effects compared to treatment with the individual medications alone in patients with diabetes.

Patients treated with a new, more concentrated insulin glargine formulation experienced similar glycemic control with fewer nocturnal and daytime hypoglycemic events compared with patients treated with the current formulation of the product.

Study results presented at ADA 2014 show Eli Lilly's investigational long-acting basal insulin analog to have similar clinical efficacy in reducing HbA1c levels as a currently approved injectable insulin glargine product, with a comparable side effect profile.